Evidence map›Paper›PMID 36731325›Full record

ArticleESMO open2023

Guideline Application in Real world: multi-Institutional Based survey of Adjuvant and first-Line pancreatic Ductal adenocarcinoma treatment in Italy. Primary analysis of the GARIBALDI survey.

M Reni, E Giommoni, F Bergamo, M Milella, L Cavanna, M C Di Marco, M Spada, S Cordio, G Aprile, G G Cardellino and 12 more

Open access · goldAbstract readMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Article in ESMO open, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed, 1 pooled it
2.3field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 1 synthesis or guideline pooled it, 10 citations in OpenAlex.

  1. Pooled it
  2. Observational
  3. Article
  4. Review
  5. Article
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

22 authors at 15 institutions in 1 country.

M ReniDepartment of Medical Oncology, Vita e Salute University, IRCCS San Raffaele Scientific Institute, Milan, Italy. Electronic address: reni.michele@hsr.it.
E GiommoniMedical Oncology, Azienda Ospedaliero-Universitaria Careggi, Florence, Italy.
F BergamoUnit of Medical Oncology 1, Department of Clinical and Experimental Oncology, Istituto Oncologico Veneto, IRCCS, Padua, Italy.
M MilellaOncology Verona, Policlinico Universitario G.B. Rossi Borgo Roma, Verona, Italy.
L CavannaOncology and Hematology Department, Oncology Unit, Piacenza General Hospital, Piacenza, Italy.
M C Di MarcoPoliclinico S. Orsola-Malpighi, Bologna, Italy.
M SpadaUnit of Oncology, San Raffaele G. Giglio Institute, Contrada Pietrapollastra - Pisciotto, Cefalù, Italy.
S CordioARNAS Garibaldi Nesima - Catania, Italy.
G AprileSan Bortolo General Hospital, ULSS8 Berica Est District - Vicenza, Italy.
G G CardellinoDepartment of Oncology, University & General Hospital, Udine Pz.le S. Maria della Misericordia 15, Udine, Italy.
E MaielloMedical Oncology, Hospital Casa Sollievo Della Sofferenza-San Giovanni Rotondo, Foggia, Italy.
I BernardiniDepartment of Oncology, Carpi and Mirandola Hospitals, Carpi e Mirandola, Italy.
M GhidiniASST Cremona - Cremona, Italy.
S BozzarelliClinical Institute Humanitas - Rozzano (Milan), Milan, Italy.
M MacchiniDepartment of Medical Oncology, Vita e Salute University, IRCCS San Raffaele Scientific Institute, Milan, Italy.
G OrsiDepartment of Medical Oncology, Vita e Salute University, IRCCS San Raffaele Scientific Institute, Milan, Italy.
I De SimoneIstituto di Ricerche Farmacologiche Mario Negri IRCCS, Milan, Italy.
Er RulliIstituto di Ricerche Farmacologiche Mario Negri IRCCS, Milan, Italy.
L PorcuIstituto di Ricerche Farmacologiche Mario Negri IRCCS, Milan, Italy.
V TorriIstituto di Ricerche Farmacologiche Mario Negri IRCCS, Milan, Italy.
C PintoAUSL-IRCCS Clinical Cancer Center of Reggio Emilia - Reggio Emilia, Italy.
GARIBALDI Study Group
Mario Negri Institute for Pharmacological Research · ITVita-Salute San Raffaele University · ITIRCCS Azienda Ospedliero-Universitaria di Bologna Policlinico di Sant'Orsola · ITOspedaliera di Piacenza · ITAzienda Ospedaliero-Universitaria Careggi · ITAzienda Sanitaria Unità Locale di Reggio Emilia · ITCasa Sollievo della Sofferenza · ITFondazione Istituto G. Giglio di Cefalù · ITHumanitas University · ITIstituti Ospitalieri di Cremona · ITIstituto Oncologico Veneto · ITOspedale Garibaldi · ITOspedale San Bortolo · ITUniversity of Verona · ITOspedale di Mirano · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundInformation about the adherence to scientific societies guidelines in the 'real-world' therapeutic management of oncological patients are lacking. This multicenter, prospective survey was aimed to improve the knowledge relative to 2017-2018 recommendations of the Italian Association of Medical Oncology (AIOM). PATIENTS AND

methodsTreatment-naive adult patients with pancreatic adenocarcinoma were enrolled. Group A received adjuvant therapy, group B received primary chemotherapy, and group C had metastatic disease. The results on patients accrued until 31 October 2019 with a mature follow-up were presented.

resultsSince July 2017, 833 eligible patients of 923 (90%) were enrolled in 44 Italian centers. The median age was 69 years (range 36-89 years; 24% >75 years); 48% were female; 93% had Eastern Cooperative Oncology Group (ECOG) performance status (PS) score of 0 or 1; group A: 16%, group B: 30%; group C: 54%; 72% Nord, 13% Center, 15% South. In group A, guidelines adherence was 68% [95% confidence interval (CI) 59% to 76%]; 53% of patients received gemcitabine and 15% gemcitabine + capecitabine; median CA19.9 was 29 (range 0-7300; not reported 15%); median survival was 36.4 months (95% CI 27.5-47.3 months). In group B, guidelines adherence was 96% (95% CI 92% to 98%); 55% of patients received nab-paclitaxel + gemcitabine, 27% FOLFIRINOX, 12% gemcitabine, and 3% clinical trial; median CA19.9 was 337 (range 0-20220; not reported 9%); median survival was 18.1 months (95% CI 15.6-19.9 months). In group C, guidelines adherence was 96% (95% CI 94% to 98%); 71% of patients received nab-paclitaxel + gemcitabine, 16% gemcitabine, 8% FOLFIRINOX, and 4% clinical trial; liver and lung metastases were reported in 76% and 23% of patients, respectively; median CA19.9 value was 760 (range 0-1374500; not reported 9%); median survival was 10.0 months (95% CI 9.1-11.1 months).

conclusionsThe GARIBALDI survey shows a very high rate of adherence to guidelines and survival outcome in line with the literature. CA19.9 testing should be enhanced; nutritional and psychological counseling represent an unmet need. Enrollment to assess adherence to updated AIOM guidelines is ongoing.

Indexed as

AdenocarcinomaCarcinoma, Pancreatic DuctalPancreatic NeoplasmsAdultAgedAged, 80 and overAntineoplastic Combined Chemotherapy ProtocolsDeoxycytidineFemaleGemcitabineHumansMaleMiddle AgedProspective StudiesDeoxycytidineGemcitabineadherence to guidelinesadjuvantfirst linepancreatic adenocarcinomaprospective survey

Identifiers

PMID36731325
PMCPMC10024128
OpenAlexW4318681069

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.